Log In
BCIQ
Print this Print this
 

Rhopressa, netarsudil ophthalmic solution 0.02% (AR-13324)

  Manage Alerts
Collapse Summary General Information
Company Aerie Pharmaceuticals Inc.
DescriptionDual inhibitor of Rho kinase and the norepinephrine transporter
Molecular Target Rho kinase ; Norepinephrine transporter
Mechanism of ActionRho kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationGlaucoma
Indication DetailsTreat glaucoma; Treat intraocular pressure (IOP) in glaucoma and ocular hypertension patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2015

Undisclosed

0

Undisclosed

Get a free BioCentury trial today